The survey showed that while the total number of active shortages has decreased to 277 in the second quarter of 2024 from a peak of 323 in 2023, the impact has remained significant, with 99% of surveyed pharmacists reporting they have experienced a shortage.
The top drug classes affected include central nervous system medications, antimicrobials, hormone agents, chemotherapy drugs and cardiology therapies. The survey highlighted that 95 new shortages were identified in 2024, with nearly half being injectable medications. Additionally, 60% of the shortages were attributed to unknown causes, with supply and demand, manufacturing issues and business decisions also being contributing factors.
Thirty-two percent 32% of respondents said they have had to ration, delay or cancel treatments.
The survey was conducted from June 23 to July 14, 2023, and polled 1,123 pharmacists, pharmacy technicians, pharmacy residents and other pharmacy professionals.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
